OncoCyte Research Development vs Net Income Analysis
OCX Stock | USD 2.44 0.09 3.56% |
OncoCyte Corp financial indicator trend analysis is much more than just breaking down OncoCyte Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OncoCyte Corp is a good investment. Please check the relationship between OncoCyte Corp Research Development and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.
Research Development vs Net Income
Research Development vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OncoCyte Corp Research Development account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between OncoCyte Corp's Research Development and Net Income is -0.78. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Income in the same time period over historical financial statements of OncoCyte Corp, assuming nothing else is changed. The correlation between historical values of OncoCyte Corp's Research Development and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of OncoCyte Corp are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Research Development i.e., OncoCyte Corp's Research Development and Net Income go up and down completely randomly.
Correlation Coefficient | -0.78 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Research Development
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in OncoCyte Corp financial statement analysis. It represents the amount of money remaining after all of OncoCyte Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from OncoCyte Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OncoCyte Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.At this time, OncoCyte Corp's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 117.1 K in 2024, whereas Discontinued Operations is likely to drop (51.3 M) in 2024.
OncoCyte Corp fundamental ratios Correlations
Click cells to compare fundamentals
OncoCyte Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
OncoCyte Corp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 39.9M | 55.4M | 159.6M | 100.1M | 74.9M | 49.1M | |
Short Long Term Debt Total | 5.9M | 8.6M | 5.7M | 3.5M | 2.9M | 4.1M | |
Other Current Liab | 2.6M | 5.3M | 9.4M | 9.2M | 4.9M | 4.7M | |
Total Current Liabilities | 4.4M | 9.0M | 14.1M | 12.1M | 7.2M | 7.6M | |
Total Stockholder Equity | 30.8M | 33.5M | 65.2M | 34.3M | 25.6M | 22.0M | |
Property Plant And Equipment Net | 3.7M | 6.5M | 8.5M | 10.9M | 5.4M | 3.8M | |
Net Debt | (16.1M) | 1.5M | (29.9M) | (16.4M) | (6.6M) | (6.9M) | |
Retained Earnings | (93.7M) | (123.7M) | (187.8M) | (260.7M) | (289.9M) | (275.4M) | |
Accounts Payable | 469K | 432K | 1.8M | 1.3M | 953K | 621.2K | |
Cash | 22.1M | 7.1M | 35.6M | 20.0M | 9.4M | 12.8M | |
Non Current Assets Total | 16.9M | 46.2M | 120.4M | 74.6M | 64.2M | 33.5M | |
Non Currrent Assets Other | 2.2M | 1.9M | 2.0M | 2.1M | 2.2M | 1.5M | |
Other Assets | 2.2M | 2.1M | 2.0M | 1.0 | 1.15 | 1.09 | |
Cash And Short Term Investments | 22.5M | 7.8M | 36.5M | 20.4M | 9.4M | 14.5M | |
Common Stock Total Equity | 124.6M | 157.2M | 253.0M | 294.9M | 339.2M | 356.1M | |
Common Stock Shares Outstanding | 2.6M | 3.3M | 4.4M | 5.5M | 7.7M | 8.0M | |
Short Term Investments | 428K | 379K | 675K | 904K | 433K | 0.0 | |
Liabilities And Stockholders Equity | 39.9M | 55.4M | 159.6M | 100.1M | 74.9M | 49.1M | |
Other Current Assets | 505K | 1.2M | 3.9M | 3.1M | 782K | 1.1M | |
Other Stockholder Equity | 948K | 343K | 37K | (5.3M) | (4.8M) | (4.5M) | |
Total Liab | 9.0M | 21.9M | 94.3M | 65.8M | 49.3M | 27.1M | |
Property Plant And Equipment Gross | 3.7M | 6.5M | 8.5M | 10.9M | 5.4M | 3.8M | |
Total Current Assets | 23.0M | 9.2M | 39.1M | 25.5M | 10.7M | 15.7M | |
Accumulated Other Comprehensive Income | (343K) | 0.0 | 37K | 39K | 49K | 51.5K | |
Short Term Debt | 1.4M | 3.2M | 3.0M | 1.6M | 1.3M | 1.7M | |
Common Stock | 124.6M | 157.2M | 253.0M | 294.9M | 310.3M | 325.8M | |
Property Plant Equipment | 614K | 3.7M | 6.5M | 8.5M | 9.8M | 10.3M | |
Net Tangible Assets | 30.8M | 9.3M | (44.7M) | (22.0M) | (19.8M) | (18.8M) | |
Long Term Debt | 1.1M | 347K | 1.9M | 1.5M | 1.7M | 905.1K | |
Retained Earnings Total Equity | (93.7M) | (123.7M) | (187.8M) | (260.7M) | (234.6M) | (222.9M) | |
Long Term Debt Total | 1.4M | 534K | 2.0M | 1.5M | 1.7M | 1.2M | |
Non Current Liabilities Total | 4.6M | 12.9M | 80.2M | 53.7M | 42.1M | 26.9M | |
Capital Lease Obligations | 2.9M | 4.7M | 4.4M | 3.5M | 2.9M | 2.8M | |
Net Invested Capital | 33.9M | 37.4M | 66.5M | 34.3M | 20.5M | 32.0M | |
Net Working Capital | 18.5M | 230K | 25.0M | 13.4M | 3.5M | 3.3M | |
Capital Stock | 124.6M | 157.2M | 253.0M | 294.9M | 310.3M | 222.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.